New Alzheimer's drug slows decline by roughly a third
Summarised from 3 outlets · Updated 17 Nov, 11:01 · Archive
A new pill that works similarly to Viagra slowed cognitive decline in early Alzheimer's patients by about a third in a major trial.
A medication called AR1001, which works similarly to Viagra, has slowed cognitive decline in Alzheimer's patients by roughly a third, according to major trial results. The drug, a phosphodiesterase-5 inhibitor, was shown to reduce clinical deterioration by 31 per cent in patients with early-stage disease who were receiving no other Alzheimer's treatments. The trial involved 604 people on no other therapies.
AR1001 works by relaxing blood vessels to increase blood flow to the brain. It is taken as a once-a-day tablet, which the Alzheimer's Society said could make treatment simpler than other disease-modifying treatments. The side effects reported were mostly mild to moderate.
The drug, developed by South Korean firm AriBio, failed to deliver statistically significant results in a broader group of patients receiving other Alzheimer's medications. Dr Richard Oakley, associate director for research and innovation at Alzheimer's Society in the UK, said the findings were 'an exciting sign that we could have a totally new treatment for early Alzheimer's disease that tackles its causes, not just its symptoms', but noted that the drug's reduced effectiveness for people taking other treatments needs further investigation.

How it is being reported
- Alzheimer's breakthrough as NHS-blocked drug 'more effective than previously thought'New five-year findings suggest an Alzheimer's drug rejected for NHS use could offer patients longer-lasting benefits than previously thought.Daily Express · 17 Nov, 14:33
- New Viagra-like drug could slow down decline of Alzheimer’sAlzheimer’s Society described the new findings as ‘an exciting sign that we could have a totally new treatment for early Alzheimer’s disease’The Independent · 17 Nov, 10:39
- New 'Viagra for the brain' pill slows clinical decline in Alzheimer's patients by a thirdThe blockbuster therapy delayed progression of the disease by the equivalent of 3.5 months after just one year in a major phase III trial.Daily Mail · 16 Nov, 21:09
In this story: AR1001 · AriBio · Alzheimer's Society · Dr Richard Oakley
This summary was written by AI from the headlines and standfirsts above, and states as fact only what at least two outlets report. How we use AI · Report a problem · Corrections log
Comments (0)